Novamab to Speak at ACCESS CHINA Partnering Forum

Oct 12th, 2023 (Shanghai) — We are glad to announce that Dr. Yakun Wan, the founder, Chairman, and CEO of Novamab, has been invited to present at ACCESS CHINA Partnering Forum on 14:45-15:00, October 17th, China time.

ACCESS CHINA Partnering Forum is the largest corporate access event between Asia and the western biopharma industry.

About Novamab

Shanghai Novamab Biopharmaceuticals Co., Ltd. is an innovative biopharmaceutical enterprise dedicated to the research and development of single domain antibody (sdAb) drugs. Novamab has independently created five core technology platforms: sdAb rapid screening platform, Pichia pastoris based CMC platform, biological drug inhalation platform, long-acting sdAb platform and bispecific/multispecific sdAb platform.

Novamab has developed more than 10 sdAb drugs covering respiratory, anti-infection, ophthalmology and oncology. LQ036 (anti IL-4Rα) and LQ043 (anti TSLP) have overturned the existing treatment methods for respiratory diseases, both of which are the world’s first inhalable sdAb drug for their respective target. Phase I trials of LQ036 have been conducted in China and Australia, both demonstrating excellent safety and tolerability. The LQ036 IND files for COPD treatment will be submitted soon. In addition, phase I trial of LQ043 in China has completed the dosing of the third group of subjects. Most moderate to severe asthmatics would benefit from the LQ036 and LQ043 considering their mechanism of action.

About the speaker

Yakun Wan, Ph.D.

Founder, Chairman, and CEO of Novamab

Dr. Yakun Wan is the founder, Chairman and CEO of Shanghai Novamab Biopharmaceuticals Co., Ltd. He completed his postdoctoral training at the University of Texas at Austin and Baylor College of Medicine. He also served as a researcher at the Institute of Systems Biology in the United States.

Dr. Yakun Wan has been committed to sdAb research for more than 17 years, with extremely rich experience in sdAb projects. He enjoys a high reputation and popularity in the field of sdAb. He had participated in the development of dozens of sdAb drugs, with one of them entering industrialization and 8 entering different clinical stages. He has applied more than 80 patents on sdAb, and published over 60 high level SCI papers. He was selected as the Hundred Talents Program of Shanghai Institute of Materia Medica, Chinese Academy of Sciences and as outstanding innovation and entrepreneurship talents in Zhangjiang National Independent Innovation Demonstration Zone etc.

About ACCESS CHINA Partnering Forum

ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. We organize a series of online and in-person partnering events since 2019 with the mission to facilitate the collaboration between Western and Eastern biotechs.

This Autumn event, as part of our quarterly series, will feature 40+ leading pharmaceutical companies delivering virtual roadshows to an audience of 500+ participants online. During the event, audience can have access to innovative biopharmas and healthcare products from worldwide.

Event Name: ACCESS CHINA Partnering Forum-2023 Autumn

Date & Time: Oct. 16th-17th, 2023

Location: Zoom Webinar

Content: Keynote Speech, Company Showcase

Participants: Pharma/Biotech senior management and BDs.

View more information at https://biotochina.org/

关于药通中国交易合作论坛2023

“ACCESS CHINA 药通中国交易合作论坛2023”于2023年10月16日至17日线上举办。自2020年始，药通中国论坛系列活动已成功举办14届，成为了海内外生物医药、医疗器械企业寻找合作的领先跨境交易路演平台。这里聚集了海内外医药界顶尖BD和管理人员，为项目交流搭建了高效的沟通渠道，为资产交易创造了宝贵的机会。

大会名称：药通中国交易合作论坛2023

大会日期：2023.10.16-17（线上）

大会内容：主题演讲、海内外优质项目路演

参会观众：海内外医药企业（药企及Biotech）高管及BD、基金高管

查看更多信息： https://biotochina.org/